# US 2021/0198378 A1 · Method for treating triple negative breast cancer combined with radiotherapy comprising administering phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 blockade

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198378 A1
- Document ID: US20210198378A1
- Status: Published application
- Kind: A1
- Application number: 16/920,933
- Filed: 2020-07-06
- Published: 2021-07-01
- Earliest claimed: 2019-12-31
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R&DB Foundation
- Inventors: In-Ah KIM; Min-Guk HAN; Bum-Sup JANG; Mi-Hyun KANG; Won-Ick CHANG
- Web page: https://patentgrep.com/patent/US20210198378A1

## CPC

- C07K 16/3015: {Breast}
- A61K 31/52: Purines, e.g. adenine
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2818: {against CD28 or CD152}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present invention provides a pharmaceutical composition and a treatment method to be combined with radiotherapy, for treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 blockade and a PI3K γ δ inhibitor, and it has excellent effects of inhibiting tumor and enhancing immunity by combining the PD-1 blockade and PI3K γ δ inhibitor with radiotherapy, compared to single therapy of each therapeutic agent.

## Claims

### Claim 1

A method of treatment of triple negative breast cancer, comprising
administering a PI13K inhibitor against one or more selected from the group consisting of PI13K delta and PI13K gamma, and a PD-1 blockade; and
performing radiotherapy.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the administering the PI13K inhibitor and the PD-1 blockade is performed by mixing the PI13K inhibitor and the PD-1 blockade and administering them together, or by administering the PI13K inhibitor and the PD-1 blockade respectively or sequentially.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the PI13K inhibitor is an inhibitor against PI13K delta and gamma.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the PI13K inhibitor is one or more selected from the group consisting of duvelisib, tenalisib and idelalisib.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the PD-1 blockade is one or more selected from the group consisting of pembrolizumabandnivolumab.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the PI13K inhibitor the PD-1 blockade are administered in a weight ratio of 9:1 to 1:9.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the radiotherapy is performed at an dose of 8 to 12 Gyin 1 to 5 times fractions (Fx), at an irradiation interval of 1 to 3 days.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the method reduces the tumor volume of a subject to 0.25 times or less of the tumor volume in a no-treatment control group.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the method of treatment increases the ratio of CD8 positive cells in tumor tissue to 2 times to 100 times compared to a no-treatment control group.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the method of treatment reduces the ratio of regulatory T cells (Treg) in tumor tissue to 60% or less than a no-treatment control group, and the ratio of myeloid-derived suppressor cells (MDSC) to 90% or less than a no-treatment control group.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the method of treatment reduces the ratio of M2 tumor-associated macrophages (M2 TAM) in tumor tissue to 50% or less than a no-treatment control group, and increases the ratio of M1 tumor-associated macrophages (M1 TAM) to 1.1 to 3 times compared to a no-treatment control group.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the triple negative breast cancer is one or more of tumors selected from the group consisting of primary tumor, metastatic tumor and recurrent tumor.
